PHATHOM PHARMACEUTICALS, INC. (PHAT) News
Filter PHAT News Items
PHAT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PHAT News Highlights
- For PHAT, its 30 day story count is now at 2.
- Over the past 20 days, the trend for PHAT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest PHAT News From Around the Web
Below are the latest news stories about PHATHOM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PHAT as an investment opportunity.
Here's Why Phathom Pharmaceuticals, Inc. (PHAT) Is a Great 'Buy the Bottom' Stock NowPhathom Pharmaceuticals, Inc. (PHAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
All You Need to Know About Phathom Pharmaceuticals, Inc. (PHAT) Rating Upgrade to BuyPhathom Pharmaceuticals, Inc. (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMeeting scheduled in March 2023 with the U.S. Food and Drug Administration (FDA) to discuss stability data and resubmission requirements for erosive GERD and H. pylori New Drug Applications FLORHAM PARK, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the fourth quarter and full year ended December 31, 202 |
Phathom Pharma Shares Fall After Formal FDA Request For Vonoprazan DataThe FDA has formally asked for additional stability data to demonstrate that levels of the impurity previously found in Phathom Pharmaceuticals Inc's (NASDAQ: PHAT) vonoprazan drug product will remain at or below the daily acceptable intake throughout the proposed shelf life of the product. The FDA cited no additional deficiencies in either letter. In August 2022, Phathom detected trace levels of a nitrosamine in vonoprazan drug product in post-approval testing as we prepared for commercial laun |
Phathom’s stock falls after receiving FDA lettersMARKET PULSE Shares of Phathom Pharmaceuticals Inc. (PHAT) tumbled about 23% in premarket trading on Friday, the day after the company said it received complete response letters from the Food and Drug Administration related to vonoprazan, which is approved for two indications and had also been submitted to the regulator as a potential treatment for erosive esophagitis. |
Phathom Pharmaceuticals Provides Regulatory UpdatesFLORHAM PARK, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced regulatory updates for its approved products, VOQUEZNA™ TRIPLE PAK™ and VOQUEZNA DUAL PAK™, approved in the U.S. for the treatment of H. pylori infection, and its pending New Drug Application (NDA) for vonoprazan for the treatment of erosive esophagitis. Phathom has |
Why Shares of Phathom Pharmaceutical Jumped This WeekInvestors are reading between the lines to see if the company is fixing its problems regarding its lead therapy. |
Great news for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Insiders acquired stock in large numbers last yearUsually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like... |
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p<0.0001)Data expected to provide the basis for future regulatory submission for vonoprazan as a daily treatment for patients with NERD, pending completion of 20-week safety extension periodOver 45 million people in the U.S. are estimated to have NERD, the largest subcategory of gastroesophageal reflux disease (GERD) |
The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and NovavaxGeron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax are included in this Analyst Blog. |